Document Detail

A novel infusible botanically-derived drug, PG2, for cancer-related fatigue: A phase II double-blind, randomized placebo-controlled study.
MedLine Citation:
PMID:  22309959     Owner:  NLM     Status:  In-Data-Review    
Purpose: This study investigated the efficacy of the botanical-derived drug, PG2, a partially purified extract of Astragalus membranaceus, as a complementary and palliative medicine for managing cancer-related fatigue (CRF). Methods: Patients with advanced cancer and moderate to severe CRF were randomized to receive either PG2 or a placebo (normal saline, NS) in the first treatment cycle (four weeks) in a double-blind manner; thereafter, on the next cycle (four weeks), all patients received open-label treatment with PG2. Results: PG2 significantly improved CRF in the NS-primed group. In the first four week cycle, PG2 administration resulted in a greater fatigue-improvement response rate than seen with NS alone. In addition, approximately 82% of patients who reported an improvement of fatigue symptoms following the first cycle of PG2 experienced sustained benefits after administration of the second treatment cycle. Among patients treated with PG2 who did not report an improvement in symptoms throughout the first treatment cycle, approximately 71% showed significant improvement after the second treatment cycle. No major or irreversible toxicities were observed with PG2 treatment. Conclusion: PG2 might be an effective and safe treatment for relieving CRF among advanced cancer patients.
Hong-Wen Chen; I-Hsin Lin; Yu-Jen Chen; Kao-Hwa Chang; Meng-Hao Wu; Wen-Hao Su; Gwo-Che Huang; Yuen-Liang Lai
Related Documents :
6336819 - Antithymocyte globulin treatment in patients with aplastic anemia: a prospective random...
7543719 - The pharmacological manipulation of fetal haemoglobin: trials using hydroxyurea and rec...
11916759 - A double-blind, placebo-controlled study of vitamin a and zinc supplementation in perso...
15253739 - Protective effect of vitamin c on 8-hydroxy-2'-deoxyguanosine level in peripheral blood...
15185069 - Combination enteral and parenteral nutrition in critically ill patients: harmful or ben...
12677149 - Randomized prospective trial of the effect of induced hypergastrinemia on the preventio...
2680009 - Progress report on the canadian multicentre trial of tetrahydroaminoacridine with lecit...
17155989 - The treatment of erectile dysfunction study: focus on treatment satisfaction of patient...
12534939 - Comparison of sibling oocyte outcomes after intracytoplasmic sperm injection and in vit...
Publication Detail:
Type:  Journal Article     Date:  2012-02-01
Journal Detail:
Title:  Clinical and investigative medicine. Médecine clinique et experimentale     Volume:  35     ISSN:  1488-2353     ISO Abbreviation:  Clin Invest Med     Publication Date:  2012  
Date Detail:
Created Date:  2012-02-07     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  7804071     Medline TA:  Clin Invest Med     Country:  Canada    
Other Details:
Languages:  eng     Pagination:  E1     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  A comparison of four approaches to account for method effects in latent state-trait analyses.
Next Document:  The Value of P wave dispersion in predicting reperfusion and infarct related artery patency in acute...